The 2025 Biopharmaceutical Competitiveness & Investment (BCI) Report, developed by Pugatch Consilium, analyzes the health investment environment in Latin America. The region scores an average of 59%, placing it behind other highly competitive emerging markets such as Singapore and Israel. Within the regional ranking, Costa Rica, Chile, and Mexico stand out as the countries with the most favorable conditions to attract biopharmaceutical investment.<\/p>\n\n\n\n
The study highlights significant progress in scientific and regulatory capabilities in some countries but also underscores persistent challenges in market access and the effective protection of intellectual property. Despite these gaps, the report is clear: Latin America has a strategic opportunity to position itself as an innovation hub, if it adopts more predictable public policies, strengthens its regulatory frameworks, and fosters closer collaboration between the public, private, and academic sectors.<\/p>\n\n\n\n